# A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

> **NCT03886831** · PHASE1 · COMPLETED · sponsor: **Prelude Therapeutics** · enrollment: 232 (actual)

## Conditions studied

- Relapsed/Refractory Advanced Solid Tumors
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Relapsed/Refractory Myelodysplasia
- Relapsed/Refractory Myelofibrosis
- Adenoid Cystic Carcinoma
- Relapsed/Refractory Mantle Cell Lymphoma
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** PRT543

## Key facts

- **NCT ID:** NCT03886831
- **Lead sponsor:** Prelude Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-11
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2023-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886831, "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03886831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*